Acquisition Transforms Bruker Advanced Supercon Business into Global Leader in Superconducting Devices, Superconductors and Advanced Technologies for Alternative Energy Research and Next-Generation Energy Infrastructure.
BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Advanced Supercon, Inc. (Bruker) today announced that it has closed the acquisition of the research instruments portion of Varian Medical Systems' ACCEL Instruments GmbH subsidiary in Bergisch-Gladbach, Germany.
Varian acquired ACCEL, including both its businesses in research instruments (RI) and proton therapy, in January 2007. In the transaction announced today, Varian is retaining the proton therapy business, which will now operate as Varian Particle Therapy, while Bruker has acquired substantially all of the assets of the RI business. The asset deal, which was signed by Bruker and Varian in February 2009, closed on April 1, 2009. Financial terms of the transaction were not disclosed.
布鲁克（Bruker）收购的RI业务是全球领导者，用于开发和制造各种高级超导和其他亚基以及用于物理和能源研究的系统以及其他科学应用。RI产品包括电子和离子Linacs，超导和正常的导电加速器腔，插入设备，其他加速器组件，中子源亚基，专用超导磁铁，超导磁铁，超导（HTS和LTS）设备，X射线和粒子光束以及真空和真空吸收器以及真空吸收器冷冻系统。
ACCEL Instruments GmbH was founded in 1993 by Dr. Udo Klein and Dr. Michael Peiniger, as a spin-off from Siemens AG. Bruker has retained Dr. Klein and Dr. Peiniger as managing directors and minority shareholders in the newly acquired RI business, which has been sub-divided into two new Bruker subsidiaries:
- RI Research Instruments GmbH is focusing on rf cavities and systems, linear accelerators, and special products for physics and energy research. It is 45% owned by its management team, and 55% by Bruker.
- Bruker Advanced Supercon GmbH专注于低温和高温超导设备，圆形加速器真空系统，梁线和X射线光学元件，以及用于物理，能源研究，医疗设备，晶体生长应用等物理学，能源研究的专业超导磁铁等。由布鲁克100％拥有。
Dr. Burkhard Prause, Chief Executive Officer of Bruker Advanced Supercon, Inc., explained: "This acquisition opens an important new chapter in the history of our Bruker Advanced Supercon business. It positions us for rapid revenue and margin growth in several exciting markets, including renewable energy research, the more stable and energy efficient electricity grids of the future, next-generation materials research and manufacturing, as well as components for cutting-edge medical devices。布鲁克（Bruker）计划在增长市场中扩展我们的新业务，例如HTS超导故障电流限制器，用于能源电网稳定，下一代半导体的水晶生长磁铁以及超导设备以及其他用于大型科学和能源研究设施的核心RI技术。我们还希望继续向Varian提供OEM产品，以支持其质子治疗业务进行晚期癌症治疗。”
Bruker Advanced Supercon，Inc。高级副总裁兼首席财务官Tom Rosa先生补充说：“每年一次，我们新获得的超导设备和能源研究系统业务预计将每年产生超过2500万美元的收入其中一个，近来的结果，在未来几年中具有显着增长的潜力。Bruker Advanced Supercon业务是当今Bruker Corporation的最小部门，但是我们有雄心勃勃的计划，以获利的增长计划，并得到了能源研究，科学基础设施投资以及材料和医学科学的最新进展的全球趋势的支持。”必威手机客户端
Bruker Advanced Supercon，Inc。董事长Joerg Laukien先生得出结论：“今天宣布的收购为我们的Bruker Advanced Supercon业务提供了重大的额外催化剂，以促进互补市场的盈利增长，并将Bruker转变为基于广泛的全球超导领导者用于替代能源研究和下一代能源基础设施的设备，超导体和先进技术。”
关于布鲁克先进的超级托克：
The Bruker Advanced Supercon subsidiary of Bruker Corporation (NASDAQ: BRKR) includes operations in Germany, in the UK and in the United States, plus the newly acquired ACCEL RI business. Bruker EAS GmbH in Germany manufactures and sells over 20,000 miles of niobium-titanium (NbTi) and niobium-tin (Nb3Sn) LTS wire annually. Bruker HTS GmbH in Germany is a leading manufacturer of both 1G BSSCO and 2G YBCO HTS materials and devices, based on its broad HTS technology platform. Bruker HTS solutions enhance the reliability and efficiency of electrical power grids and large energy demanding applications. Its proprietary SuperFast™ superconducting fault current limiter (SFCL) has the potential to enhance power grid reliability, and its HTS current leads can dramatically reduce electrical losses in large industrial and research magnets. Conductors and components made by Bruker HTS are being used to build new generations of compact high power devices such as HTS motors, generators, cables and transformers, as well as high field magnets for medical and research applications. Hydrostatic Extrusions Ltd. in the UK offers the light-weight Cuponal™ conductor for the aviation industry. Bruker Advanced Supercon, Inc. opened business development and customer support operations in the U.S. in 2008. For more information:www.advancedsupercon.comorwww.fatactor.com。
Bruker Forward Looking Statements:
本新闻稿中包含的任何陈述都不描述历史事实，可能构成前瞻性陈述，因为该术语是在1995年的《私人证券诉讼改革法》中定义的。有许多风险和不确定性。可能导致实际结果与当前期望有重大差异的因素包括但不限于与全球经济条件不利变化和资本市场波动性的不利变化有关的风险和不确定性，我们已经获得或已获得的企业整合将来可能会收购我们的产品的技术，产品开发和市场接受，产品的成本和价格，制造，竞争，依赖协作合作伙伴和主要供应商，资本支出和政府资助政策，政府法规的变化，知识产权，诉讼和外币波动的暴露。这些因素和其他因素在向SEC提交的文件中更详细地识别和描述，包括但不限于我们关于10-K表格的年度报告，即我们关于表格10-Q的最新季度报告以及我们有关表格8--的当前报告K.除法律要求之外